Tri-mili Kit
Product Images NDC 65862-777

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Tri-mili (NDC 65862-777). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Blister Pack (Norgestimate Fig1)

An instructional diagram for the Tri-Mili kit showing how to pick and peel the correct day label to place on the medication pack. The illustration depicts the arrangement of tablets by color (white, light blue, dark blue, green) and dosage strengths for norgestimate and ethinyl estradiol tablets, indicating the sequence and days of the week for administration.*

FDA Label Image

Blister Pack (Norgestimate Fig2)

Illustration of the Tri-Mili kit tablet arrangement showing a 4-week cycle. Four white tablets for Week 1, four light blue tablets for Week 2, four dark blue tablets for Week 3 with active ingredient strengths listed, and seven green tablets for Week 4. The image guides the weekly tablet sequence for this oral contraceptive kit containing norgestimate and ethinyl estradiol.*

FDA Label Image

Figure 3 (Norgestimate Fig3)

This is a forest plot chart depicting odds ratios (OR) and relative risks (RR) comparing current versus never use of combined oral contraceptives (COC) across multiple studies. The chart shows point estimates with confidence intervals for each study, comparing the risk or odds of an outcome between COC users and non-users.*

FDA Label Image

Figure-4 (Norgestimate Fig4)

A vertical effectiveness chart illustrating pregnancy rates per 100 women per year by contraceptive method. It ranges from fewer pregnancies at the top to more pregnancies at the bottom. Methods listed include implants, injections, intrauterine devices, sterilization, birth control pills, skin patch, vaginal ring with hormones, condoms, diaphragm, abstinence during fertile days, spermicide, withdrawal, and no birth control.*

FDA Label Image

Figure-5 (Norgestimate Fig5)

Illustration showing the Tri-Mili kit containing norgestimate and ethinyl estradiol tablets in four color-coded rows: white, light blue, dark blue, and green. A hand is placing a day label strip on the kit with the days of the week to help track daily tablet intake starting from Sunday through Saturday.*

FDA Label Image

Package Label-principal Display Panel- Carton Label (1x28's) (Norgestimate Fig6)

An instructional diagram for the Tri-Mili kit showing a 4-week cycle of oral tablets. The diagram displays four rows of circles indicating pills to be taken each day from Sunday to Saturday. The colors white, light blue, dark blue, and green represent different weeks and dosages of norgestimate and ethinyl estradiol tablets. The dark blue tablets are labeled with specific dosages. Arrows and labeling indicate the sequence to start and follow through the weekly schedule.*

FDA Label Image

Norgestimate Fig7

Packaging label for Tri-Mili, a kit containing norgestimate and ethinyl estradiol tablets USP in strengths of 0.180 mg/0.035 mg, 0.215 mg/0.035 mg, and 0.250 mg/0.035 mg. The label indicates a blister card of 28 tablets, with seven tablets each of white, light blue, dark blue, and green coatings. Distributed by Aurobindo Pharma USA, Inc. and made in India.*

FDA Label Image

Structure (Norgestimate Str)

Chemical structure of Norgestimate and Ethinyl Estradiol depicted in a black and white line diagram. The image shows the molecular formula layouts for both active ingredients included in Tri-Mili, a prescription drug product by Aurobindo Pharma Limited.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.